SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Abstract The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	B.Sc. Sara Protić, M.Sc. Milica Crnoglavac Popović, M.Sc. Nevena Kaličanin, Dr. Olivera Prodanović, Dr. Milan Senćanski, Dr. Jelena Milićević, Dr. Kristina Stevanović, Dr. Vladimir Perović, Dr. Slobodan Paessler, Dr. Radivoje Prodanović, Dr. Sanja Glišić
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley-VCH 2024-11-01
Ráidu:	ChemistryOpen
Fáttát:	antiviral therapy drug repurposing fidaxomicin SARS-CoV-2 PLpro in vitro
Liŋkkat:	https://doi.org/10.1002/open.202400091
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!